Article

The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients

Foot and Ankle Service, Department of Orthopaedic Surgery, 1000 North Oak Avenue, Marshfield Clinic, Marshfield, WI 54449, USA.
Foot & Ankle International (Impact Factor: 1.63). 02/2003; 24(1):40-4.
Source: PubMed

ABSTRACT The records of 104 patients who underwent reconstructive foot and ankle surgery for deformities secondary to rheumatoid arthritis were reviewed. The use of rheumatoid chemotherapeutic agents, age, sex, rheumatoid nodule status, and the number of concurrent surgical procedures performed was analyzed to determine any association with the postoperative outcome for wound healing and infectious complications. The 104 patients, ranging in age from 23 to 83 years, underwent 725 operative procedures. An overall 32% complication rate was recorded. Analysis of five specific rheumatoid chemotherapeutic agents (NSAIDs, steroids, methotrexate, hydroxychloroquine, gold), age, sex, number of operative procedures performed, and presence of rheumatoid nodules, either alone or in combination, failed to prove a statistical association with either a healing or infectious postoperative complication.

0 Followers
 · 
127 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Einfhrung von Biological Modifiern, wie Anti-Tumornekrosefaktoren (TNF) und Interleukin-1- (IL-1-) Rezeptor-Antagonisten, stellte einen wesentlichen Fortschritt in der Behandlung der rheumatoiden Arthritis (RA) dar. Die neuen Medikamente sind gut vertrglich und verbessern die Symptome und Zeichen der RA. Aufgrund des immunsuppressiven Effektes wurde ein erhhtes Risiko fr Infektionen vermutet. In Bezug auf Adalimumab besttigte sich dies jedoch in den ersten Studien nicht. Patienten mit RA haben ein erhhtes Risiko fr postoperative Infekte und Wundheilungsstrungen, da sie unter einer systemischen Krankheit leiden und immunsuppressive Medikamente einnehmen. Wir berichten ber einen 57-jhrigen Patienten mit langjhriger hochaktiver RA, bei dem unter Therapie mit Adalimumab 40mg einmal wchentlich ein rekonstruktiver Vorfueingriff mit Beckenkamminterponat und Weichteil-Release aufgrund von ausgeprgten Deformitten durchgefhrt wurde. Postoperativ entwickelte sich ein ausgeprgter Wundinfekt mit verzgerter Wundheilung, Wunddehiszenz und Pseudoarthrosenbildung. Der Infekt trat auf, obwohl Adalimumab 8Tage vor dem Eingriff pausiert wurde. Die Halbwertszeit von Adalimumab betrgt 10–13,6Tage nach einer einmaligen intravensen Gabe. Ob Patienten unter Therapie mit Adalimumab zu postoperativen Infekten neigen, ist nicht klar. Zudem ist nicht geklrt, ob Adalimumab perioperativ zu pausieren ist, um ein eventuelles Infektionsrisiko zu senken. Prospektive Studien wren wnschenswert, um die Gefahr von perioperativen (Wund-) Infekten unter Therapie mit Anti-TNF zu beurteilen.Tumor necrosis factor (TNF) blocking agents, such as adalimumab, are well tolerated and provide improvement in the symptoms and signs of rheumatoid arthritis (RA). Due to its immunosuppressive effect, an increased risk of infection has been suggested, but so far no differences between adalimumab and placebo groups habe been found in pivotal trials. Patients with RA succumb to postoperative complications because they have a systemic disease and use medication with immunosuppressive effects. We report on a patient with longstanding, active RA who had received adalimumab 40mg every other week with prolonged infection, wound dehiscence and pseudoarthrosis following reconstructive forefoot surgery due to deformities secondary to RA. The postoperative infection occurred although adalimumab therapy had been stopped 8days before surgery. The half-life of adalimumab is 10.0–13.6 days following a single intravenous dose. Whether patients under therapy with adalimumab are at an increased risk of developing postoperative complications is unclear, a retrospective analysis of the pivotal studies would be helpful in estimating the risk of perioperative (wound) infections in patients receiving anti-TNF. Moreover, it is not clear when therapy should be stopped prior to surgical intervention. Obviously prospective clinical trials would be more convincing.
    Zeitschrift für Rheumatologie 01/2006; 65(8):725-727. DOI:10.1007/s00393-006-0081-0 · 0.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with rheumatoid arthritis (RA), an inflammatory arthritis that can destroy joint structures, are often on multiple medications to control disease activity. These medications may have significant toxicities and side effects. Over the course of their lifetime, patients with this disease often require orthopedic procedures, including total joint arthroplasty, and the medications they are taking present management issues specific to the perioperative period. As many of these medications are immunosuppressive, the concern for postoperative infection and delayed wound healing are particularly worrisome. We conducted a review of the available literature pertaining to the perioperative use of the most commonly prescribed medications for RA. Although the existing data directly addressing perioperative complications in orthopedic surgery is sparse, information on relevant complications resulting from the general use of these drugs may be used as a basis for conservative recommendations.
    HSS Journal 10/2006; 2(2):141-7. DOI:10.1007/s11420-006-9012-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumor necrosis factor (TNF) blocking agents, such as adalimumab, are well tolerated and provide improvement in the symptoms and signs of rheumatoid arthritis (RA). Due to its immunosuppressive effect, an increased risk of infection has been suggested, but so far no differences between adalimumab and placebo groups have been found in pivotal trials. Patients with RA succumb to postoperative complications because they have a systemic disease and use medication with immunosuppressive effects. We report on a patient with longstanding, active RA who had received adalimumab 40 mg every other week with prolonged infection, wound dehiscence and pseudoarthrosis following reconstructive forefoot surgery due to deformities secondary to RA. The postoperative infection occurred although adalimumab therapy had been stopped 8 days before surgery. The half-life of adalimumab is 10.0-13.6 days following a single intravenous dose. Whether patients under therapy with adalimumab are at an increased risk of developing postoperative complications is unclear, a retrospective analysis of the pivotal studies would be helpful in estimating the risk of perioperative (wound) infections in patients receiving anti-TNF. Moreover, it is not clear when therapy should be stopped prior to surgical intervention. Obviously prospective clinical trials would be more convincing.
    Zeitschrift für Rheumatologie 01/2007; 65(8):725-7. · 0.46 Impact Factor
Show more